Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.51 |
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | ITK | Q08881 | 4/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27612655 | 0.86 | SYK (0.49) | SYKEGFRITKPTK2FGFR1 | |
| SCHEMBL657340 | 0.81 | EGFR (0.56) | SYKEGFRITKPTK2LRRK2 | |
| SCHEMBL3839582 | 0.80 | SYK (0.63) | SYKEGFRITKPTK2FGFR1 | |
| SCHEMBL28757118 | 0.78 | AURKA (0.63) | SYKEGFRITK | |
| SCHEMBL27632174 | 0.77 | SYK (0.58) | SYKEGFRITK | |
| SCHEMBL657714 | 0.75 | EGFR (0.65) | SYKEGFRITK | |
| SCHEMBL656368 | 0.75 | EGFR (0.61) | SYKEGFRITK | |
| SCHEMBL659274 | 0.74 | SYK (0.67) | SYKEGFRITK | |
| SCHEMBL23754871 | 0.73 | PTK2 (0.72) | SYKEGFRITKPTK2FGFR1 | |
| SCHEMBL30086260 | 0.73 | PTK2 (0.72) | SYKEGFRITKPTK2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |